98 related articles for article (PubMed ID: 16761619)
1. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
J Exp Clin Cancer Res; 2006 Mar; 25(1):59-64. PubMed ID: 16761619
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining.
Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Jesionek-Kupnicka D; Pasz-Walczak G; Watala C; Kordek R
Jpn J Clin Oncol; 2006 Mar; 36(3):142-9. PubMed ID: 16520356
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of cyclin E expression in operable breast cancer.
Potemski P; Kusińska R; Pasz-Walczak G; Piekarski JH; Watała C; Płuciennik E; Bednarek AK; Kordek R
Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
[TBL] [Abstract][Full Text] [Related]
4. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
5. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.
Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Jesionek-Kupnicka D; Watala C; Kordek R
Pathol Res Pract; 2006; 202(7):491-5. PubMed ID: 16678980
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
12. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
13. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
14. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications.
Donnellan R; Kleinschmidt I; Chetty R
Hum Pathol; 2001 Jan; 32(1):89-94. PubMed ID: 11172300
[TBL] [Abstract][Full Text] [Related]
16. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V
Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
[TBL] [Abstract][Full Text] [Related]
18. [The relationship between expression of interleukin-8 and prognosis of breast cancer].
Yao C; Wang SM; Xie D; Wu HX; Chen DY; Lin Y
Zhonghua Wai Ke Za Zhi; 2006 Jul; 44(13):900-3. PubMed ID: 17067482
[TBL] [Abstract][Full Text] [Related]
19. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
20. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
